Noticias y Actividades de Norgine France

Norgine France pertenece a Norgine. Norgine tiene presencia directa en 3 países.

Norgine posee 3 subsidiarias incluyendo Norgine France, Norgine UK y Norgine Ventures.

Ellos se encuentran en:

• Farmacia75%
• Fondo25%

Ver el organigrama con sus 7 ejecutivos principales

Biografías más buscadas en Norgine France

• Cyril Tavier, General Manager
• Stephanie Magnier-Abraham, Regulatory Affairs Director and Head Ph...
• Sandrine Marie, Commercial Management Controller and Customer Rela...

Crear su alerta
para seguir los movimientos de los ejecutivos en Norgine France.

Norgine tiene 1.839 competidores entre los que se incluyen Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) y Sanofi (Francia).

Popular M&A news in Farmacia

• Pathos se convierte en un unicornio con su recaudación de fondos de 365 millones de dólares. (publicado el 4 de julio de 2025).
• Vor Biopharma and Incyte have announced they will merge  (publicado el 30 de junio de 2025)..
• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado el 16 de junio de 2025).

Otros contactos sugeridos en el sector Farmacia

• Linh Kha - Senior Vice President and General Manager, Japan Asia-Pacific en Amgen
• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Seth Harrison - Chairman and Director en Braeburn Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Norgine France

• Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - Norgine
• Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia - Norgine
• Norgine Announces Appointment of New CEO Janneke van der Kamp - Norgine
• Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - Norgine
• Pedmarqsi® (anhydrous sodium thiosulfate) recommended by NICE for patients 1 month to 17 years of age in England and Wales for the prevention of cisplatin-induced hearing loss - Norgine
• European study highlights need to improve the quality of conversations about induction of labour (IoL) in  clinical settings - Norgine
• Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer - Norgine
• NORGINE LAUNCHES ZIVEREL® IN AUSTRIA, BELGIUM, LUXEMBOURG AND SWITZERLAND - NorgineNORGINE LAUNCHES ZIVEREL® IN AUSTRIA, BELGIUM, LUXEMBOURG AND SWITZERLAND - Norgine
• LYMPHOSEEK®▼ (99mTc-tilmanocept) LAUNCHES IN EUROPE - NorgineLYMPHOSEEK®▼ (99mTc-tilmanocept) LAUNCHES IN EUROPE - Norgine
• NORGINE B.V. ACQUIRES AZANTA A/S, STRENGTHENING ITS POSITION AS A LEADING EUROPEAN SPECIALIST PHARMACEUTICAL COMPANY - NorgineNORGINE B.V. ACQUIRES AZANTA A/S, STRENGTHENING ITS POSITION AS A LEADING EUROPEAN SPECIALIST PHARMACEUTICAL COMPANY - Norgine
• View more press releases Close

Redes sociales sobre Norgine France

• Norgine France en Wikipedia, Google News y Yahoo Finance
• Norgine France en LinkedIn, Twitter y YouTube